Compare MakeMyTrip Ltd (MMYT) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Tempus AI — how do they compare? MakeMyTrip Ltd trades at $44.73 (market cap $4.09B), while Tempus AI trades at $70.93 (market cap $12.58B). The key difference: Tempus AI is far larger — about 3.1× MakeMyTrip Ltd's market cap, and Tempus AI is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Tempus AI for 23 Days on average.
| MMYT | TEM | |
|---|---|---|
Market Cap | $4.09B | $12.58B |
Volume | 1,828,010 | 7,444,569 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $94.43 | $99.28 |
52-Week Low | $36.30 | $41.55 |
Typical Hold Time | 12 Days | 23 Days |
Enterprise Value | $4.75B | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMYT trades at $44.73, up 3.04% today, but technical indicators signal a bearish trend with support at $42. The stock shows mixed earnings, missing Q4 2025 and Q2 2026 estimates but beating Q1 2026. Revenue grew to $978.34M in 2025, though net income margin is thin at 3.23%. Analyst consensus is strongly bullish with a $77 price target, but cash flow turned negative in 2026, and debt-to-asset ratio surged, raising financial stability concerns.
The outlook is bifurcated: strong analyst support and a high target suggest upside, but deteriorating cash flow, rising leverage, and bearish technicals pose significant risks. Investors should weigh the potential from operational resilience and a planned Indian listing against financial volatility and macroeconomic pressures on travel demand.
Tempus AI (TEM) trades at $70.93, up 0.91% today, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, with 2026 revenue reaching $1.4B, but remains unprofitable with a net margin of -17.77%. Recent FDA clearance for its ECG-MR AI product and positive ESMO Congress abstracts highlight innovation momentum, though negative cash flow from operations and insider selling pose concerns.
Outlook is cautiously optimistic given 64% buy ratings and a $72.60 consensus target, but profitability challenges and high valuation multiples (P/S 8.61, P/B 28.27) demand scrutiny. Key risks include sustained losses, competitive pressures, and reliance on financing activities for liquidity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
